

Contents

Acknowledgment XIX

Preface XXI

List of Contributors XXIII

Part A Pathogens 1

Part I Bacteria 3

1	<i>Bacillus anthracis</i>: Anthrax 5
	<i>Markus Antwerpen, Paola Pilo, Pierre Wattiau, Patrick Butaye, Joachim Frey, and Dimitrios Frangoulidis</i>
1.1	Introduction 5
1.2	Characteristics of the Agent 5
1.3	Diagnosis 6
1.3.1	Phenotypical Identification 6
1.3.2	Growth Characteristics 6
1.3.3	Antibiotic Resistance 7
1.3.4	Phage Testing and Biochemistry 8
1.3.5	Antigen Detection 8
1.3.6	Molecular Identification 8
1.3.6.1	Virulence Plasmid pXO1 8
1.3.6.2	Virulence Plasmid pXO2 10
1.3.7	Chromosome 10
1.3.8	MLVA, SNR, and SNP Typing 11
1.3.9	Serological Investigations 11
1.4	Pathogenesis 12
1.4.1	Animals 12
1.4.2	Humans 12
1.5	Clinical and Pathological Findings 13
1.5.1	Oropharyngeal Anthrax 14
1.5.2	Abdominal or Intestinal Anthrax 14
1.5.3	Inhalational or Pulmonary Anthrax 14
1.6	Epidemiology 15

1.7	Conclusion	15
	References	16
2	<i>Brucella</i> Species: Brucellosis	19
	<i>Sally J. Cutler, Michel S. Zygmunt, and Bruno Garin-Bastuji</i>	
2.1	Introduction	19
2.2	Characteristics of the Agent	20
2.3	Diagnosis	22
2.3.1	Immunological Approaches	25
2.3.2	Polymerase Chain Reaction Assays	25
2.4	Pathogenesis	26
2.5	Clinical and Pathological Findings	27
2.6	Epidemiology, Molecular Typing, and Control Strategies	29
2.6.1	Epidemiology	29
2.6.2	Molecular Typing Methods	29
2.6.3	Control Strategies	31
2.7	Conclusions	31
	References	32
3	<i>Burkholderia mallei</i>: Glanders	37
	<i>Lisa D. Sprague and Mandy C. Elschner</i>	
3.1	Introduction	37
3.2	Characteristics of the Agent	37
3.3	Diagnosis	38
3.3.1	Cultural Identification	38
3.3.2	Molecular Based Methods	39
3.3.3	Antigen Detection	39
3.3.4	Serology	39
3.4	Clinical and Pathological Findings in Humans	40
3.5	Clinical and Pathological Findings in Animals	41
3.6	Epidemiology	42
3.7	Molecular Typing	43
3.8	Conclusions	43
	References	43
4	<i>Burkholderia pseudomallei</i>: Melioidosis	47
	<i>Lisa D. Sprague and Mandy C. Elschner</i>	
4.1	Introduction	47
4.2	Characteristics of the Agent	47
4.3	Diagnosis	48
4.3.1	Cultural Identification	48
4.3.2	Antigen Detection	49
4.3.3	Molecular Based Methods	49
4.3.4	Serology	49

4.4	Clinical and Pathological Findings in Humans	50
4.5	Clinical and Pathological Findings in Animals	50
4.6	Epidemiology	52
4.6.1	Molecular Typing	52
4.7	Conclusions	52
	References	53
5	<i>Coxiella burnetii</i>: Q Fever	57
	<i>Matthias Hanczaruk, Sally J. Cutler, Rudolf Toman, and Dimitrios Frangoulidis</i>	
5.1	Introduction	57
5.2	Characteristics of the Agent	58
5.3	Diagnosis	59
5.3.1	Direct Detection	59
5.3.2	<i>C. burnetii</i> Cultivation	59
5.3.3	Detection of <i>C. burnetii</i> Specific DNA	60
5.3.4	Serology	61
5.4	Pathogenesis	62
5.5	Clinical and Pathological Findings	63
5.5.1	Acute Q Fever	63
5.5.2	Chronic Q Fever	64
5.6	Epidemiology, Including Molecular Typing	64
5.6.1	Plasmid Types	64
5.6.2	RFLP	65
5.6.3	IS1111 Typing	65
5.6.4	Multispacer Sequence Typing	65
5.6.5	MLVA Typing	66
5.7	Conclusion	66
	References	66
6	<i>Francisella tularensis</i>: Tularemia	71
	<i>Anders Johansson, Herbert Tomaso, Plamen Padeshki, Anders Sjöstedt, Nigel Silman, and Paola Pilo</i>	
6.1	Introduction	71
6.2	Characteristics of the Agent	72
6.3	Diagnosis	72
6.3.1	Serology	72
6.3.2	Direct Isolation	72
6.3.3	Phenotypical Characteristics	73
6.3.4	Molecular Biology Tools for Identification	73
6.4	Pathogenesis	73
6.5	Clinical and Pathological Findings	74
6.5.1	Animals	74
6.5.2	Humans	74
6.6	Epidemiology and Molecular Typing	77

6.7	Conclusion	79
	References	80
7	<i>Yersinia pestis</i>: Plague	85
	<i>Anne Laudisoit, Werner Ruppitsch, Anna Stoeger, and Ariane Pietzka</i>	
7.1	Introduction	85
7.2	Characteristics of the Agent	88
7.2.1	The Plague Bacterium: <i>Yersinia pestis</i>	88
7.2.1.1	<i>Yersinia pestis</i> Microbiology	89
7.2.1.2	<i>Yersinia pestis</i> Virulence Markers and Pathogenesis	89
7.2.1.3	Chromosomal Virulence Genes	90
7.2.1.4	<i>Yersinia pestis</i> Variants	92
7.2.2	Molecular Typing	92
7.3	Pathogenesis	93
7.3.1	Clinical and Pathological Signs	93
7.3.2	Diagnosis	95
7.3.2.1	Plague Prevention and Treatment	96
7.3.3	Plague as a Biological Weapon	97
7.4	Epidemiology	98
7.4.1	Plague Distribution Today	99
7.4.2	Plague in Its Historical Perspective	100
7.4.3	An Updated Plague Cycle?	102
7.4.3.1	Flea-Borne Plague Transmission	103
7.4.4	Classical Plague Cycle	107
7.5	Conclusion	109
	References	110
8	<i>Rickettsia</i> Species: Rickettsioses	123
	<i>Alice N. Maina, Stephanie Speck, Eva Spitalska, Rudolf Toman, Gerhard Dobler, and Sally J. Cutler</i>	
8.1	Introduction	123
8.2	Characteristics of the Agent	124
8.3	Phylogenetic Classification of Rickettsiae	126
8.3.1	Typhus Fever Group	126
8.3.2	Spotted Fever Group	128
8.3.3	Transitional Group Rickettsiae	129
8.3.4	Ancestral Group Rickettsiae	129
8.4	Diagnosis	130
8.4.1	Clinical Diagnosis	130
8.4.2	Laboratory Diagnostics	131
8.5	Pathogenesis	134
8.5.1	Clinical and Pathological Findings	136
8.6	Epidemiology	138
8.7	Conclusions	142
	Acknowledgments	142
	References	143

9	<i>Mycobacterium tuberculosis</i>: Tuberculosis	149
	<i>Stefan Panaiotov, Massimo Amicosante, Marc Govaerts, Patrick Butaye, Elizabetha Bachiyiska, Nadia Brankova, and Victoria Levterova</i>	
9.1	Introduction	149
9.2	Diagnostic Microbiology of Mycobacteria	150
9.3	Staining and Microscopic Examination	151
9.4	Cultivation of Mycobacteria	152
9.5	Identification of Mycobacteria from Culture	153
9.6	Identification of Mycobacteria Directly from Clinical Specimens	154
9.7	Immunological Tests for the Diagnosis of <i>Mycobacterium tuberculosis</i> Infection	155
9.8	Molecular Epidemiology of Tuberculosis	157
9.9	Theoretical Principles of Typing	160
9.10	Performance Criteria Applied in Selecting the Method for Molecular Typing of Microorganisms	160
9.10.1	Reproducibility	160
9.10.2	Discriminatory Power	160
9.10.3	Typeability	161
9.11	Genetic Elements in <i>M. tuberculosis</i> that Contribute to DNA Polymorphism: Current Methods Applied for Genotyping of <i>M. tuberculosis</i>	161
9.12	IS6110-RFLP Analysis	161
9.13	Spacer Oligonucleotide Typing – Spoligotyping	162
9.14	VNTR and MIRU Analysis	163
9.15	Single Nucleotide Polymorphism	165
9.16	The Clustering Question?	166
9.17	Conclusions	167
	References	167
	Part II Viruses	173
10	Influenza Virus: Highly Pathogenic Avian Influenza	175
	<i>Chantal J. Snoeck, Nancy A. Gerloff, Radu I. Tanasa, F. Xavier Abad, and Claude P. Muller</i>	
10.1	Introduction	175
10.2	Characteristics of the Agent	175
10.2.1	Nomenclature	175
10.2.2	Genome and Protein Structure	176
10.2.3	Viral Replication	176
10.2.4	Antigenic Drift and Antigenic Shift	176
10.3	Pathogenesis	177
10.3.1	Reservoir	177
10.3.2	Low and Highly Pathogenic Influenza Viruses	177
10.3.3	Molecular Determinants of Pathogenicity	178
10.4	Clinical and Pathological Findings	179

10.4.1	HPAI (H5N1) Infection in Animals	179
10.4.2	HPAI (H5N1) Infection in Humans	180
10.5	Diagnosis	181
10.5.1	Direct Diagnosis	181
10.5.2	Indirect Diagnosis	181
10.5.3	Pathotyping	182
10.6	Evolution and Geographic Spread of HPAI (H5N1) Viruses	182
10.6.1	Chronology of H5N1 Virus	182
10.6.1.1	First Wave	182
10.6.1.2	Second Wave	183
10.6.1.3	Third Wave	183
10.6.2	Focus on Africa	185
10.7	Epidemiology of Other Influenza Subtypes	187
10.7.1	HPAI Virus Outbreaks	187
10.7.2	LPAI Virus Outbreaks	188
10.8	Conclusion	188
	References	189
11	Variola: Smallpox	201
	<i>Andreas Nitsche and Hermann Meyer</i>	
11.1	Introduction	201
11.2	Variola Virus	201
11.3	Human Monkeypox	202
11.4	Vaccinia Virus	203
11.5	Cowpox Virus	203
11.6	Collection of Specimens	204
11.7	Real-Time Polymerase Chain Reaction	204
11.8	Evaluation of Real-Time PCR Assays	205
11.9	Real-Time PCR Assays with Hybridization Probes	206
11.10	Real-Time PCR Assays with 5' Nuclease Probes	207
11.11	Other Real-Time PCR Formats	208
11.12	Conclusions	209
	References	209
12	Arenaviruses: Hemorrhagic Fevers	211
	<i>Amy C. Shurtleff, Steven B. Bradfute, Sheli R. Radoshitzky, Peter B. Jahrling, Jens H. Kuhn, and Sina Bavari</i>	
12.1	Characteristics	211
12.2	Epidemiology	212
12.2.1	Old World Arenaviruses	212
12.2.2	New World Arenaviruses	213
12.3	Clinical Signs	214
12.3.1	Old World Arenaviral Hemorrhagic Fevers	214
12.3.2	New World Arenaviral Hemorrhagic Fevers	214
12.4	Pathological Findings	215

12.4.1	Old World Arenaviral Hemorrhagic Fevers	215
12.4.2	New World Arenaviral Hemorrhagic Fevers	217
12.5	Pathogenesis of Old and New World Hemorrhagic Fevers	218
12.6	Diagnostics	223
12.6.1	Serological Tests	223
12.7	PCR	224
12.7.1	Virus Culture and Antigen Testing	224
12.8	Disclaimer	224
	References	224
13	Filoviruses: Hemorrhagic Fevers	237
	<i>Victoria Wahl-Jensen, Sheli R. Radoshitzky, Sina Bavari, Peter B. Jahrling, and Jens H. Kuhn</i>	
13.1	Characteristics	237
13.2	Epidemiology	239
13.3	Clinical Signs	242
13.4	Pathological Findings	243
13.5	Pathogenesis	245
13.6	Diagnostic Procedures	246
13.7	Disclaimer	247
	References	247
14	Bunyavirus: Hemorrhagic Fevers	253
	Introduction	253
14.1	Crimean Congo Hemorrhagic Fever Virus: an Enzootic Tick Borne Virus Causing Severe Disease in Man	255
	<i>Ali Mirazimi</i>	
14.1.1	Introduction	255
14.1.2	Characteristics	256
14.1.3	Epidemiology	256
14.1.4	Clinical and Pathological Findings	257
14.1.5	Pathogenesis	257
14.1.6	Diagnosis	258
14.1.6.1	Virus Isolation	259
14.1.6.2	Molecular Methods	259
14.1.6.3	Antigen Detection	259
14.1.6.4	Serology	259
	References	259
14.2	Rift Valley Fever Virus: a Promiscuous Vector Borne Virus	263
	<i>Manfred Weidmann, F. Xavier Abad, and Janusz T. Paweska</i>	
14.2.1	Introduction	263
14.2.2	Characteristics of the Agent	263
14.2.3	Epidemiology	264

14.2.4	Clinical and Pathological Findings in Humans	265
14.2.5	Prophylaxis and Treatment	265
14.2.6	Pathogenesis	266
14.2.7	Diagnosis and Surveillance	267
14.2.8	Conclusions	268
	References	268
14.3	Hantaviruses: the Most Widely Distributed Zoonotic Viruses on Earth	273
	<i>Jonas Klingström</i>	
14.3.1	Introduction	273
14.3.2	Characteristics of the Agent	274
14.3.3	Epidemiology	276
14.3.4	Clinical Findings	277
14.3.4.1	HFRS	277
14.3.4.2	HCPS	278
14.3.5	Pathogenesis	279
14.3.6	Diagnosis	279
14.3.6.1	Serology	279
14.3.6.2	Virus Detection	280
	References	281
Part B	Practical Guidelines	291
	Part I Bacteria	293
1	<i>Bacillus anthracis</i>	295
	<i>Markus Antwerpen, Paola Pilo, Pierre Wattiau, Patrick Butaye, Joachim Frey, and Dimitrios Frangoulidis</i>	
	Recommended Respiratory Protection	295
	Recommended Personal Protective Equipment	295
	Best Disinfection	295
	Surface and Equipment	295
	Skin/Wound Disinfection	296
	Best Decontamination	296
	Prevention	296
	Case Reports, Ongoing Clinical Trials	296
	Post Exposure Prophylaxis	296
	Known Laboratory Accidents	296
	Procedure Recommended in the Case of Laboratory Spill or Other Type of Accident	297
	Treatment of Disease	297
	Clinical Guidelines	297

- 2** ***Brucella Species*** 298
Sally J. Cutler, Michel S. Zygmunt, and Bruno Garin-Bastuji
Recommended Respiratory Protection 298
Recommended Personal Protective Equipment 298
Best Disinfection 298
Best Decontamination 299
Prevention 299
Post Exposure Prophylaxis 299
Known Laboratory Accidents 299
Procedure Recommended in Case of Laboratory Spill or Other Type of
Accident 300
Treatment of Disease 300
Clinical Guidelines 300
- 3** ***Burkholderia mallei: Glanders*** 301
Lisa D. Sprague and Mandy C. Elschner
Recommended Respiratory Protection 301
Recommended Personal Protective Equipment 301
Best Disinfection 301
Best Decontamination 301
Prevention 301
Case Reports, Ongoing Clinical Trials 302
Post Exposure Prophylaxis 302
Known Laboratory Accidents 302
Procedure Recommended in Case of Laboratory Spill or Other Type of
Accident 302
Treatment of Disease 302
Clinical Guidelines 302
References 302
- 4** ***Burkholderia pseudomallei: Melioidosis*** 303
Lisa D. Sprague and Mandy C. Elschner
Recommended Respiratory Protection 303
Recommended Personal Protective Equipment 303
Best Disinfection 303
Best Decontamination 303
Prevention 303
Post Exposure Prophylaxis 304
Known Laboratory Accidents 304
Procedure Recommended in Case of Laboratory Spill or Other Type of
Accident 304
Treatment of Disease 304
Clinical Guidelines 304
References 305

- 5** ***Coxiella burnetii*: Q Fever** 306
Matthias Hanczaruk, Sally J. Cutler, Rudolf Toman, and Dimitrios Frangoulidis
Recommended Respiratory Protection 306
Recommended Personal Protective Equipment 306
Best Disinfection 306
Surface and Equipment 306
Skin Disinfection 307
Best Decontamination 307
Prevention 307
Post Exposure Prophylaxis 307
Known Laboratory Accidents 307
Procedure Recommended in Case of Laboratory Spill or Other Type of Accident 308
Treatment of Disease 308
Clinical Guidelines 308
- 6** ***Francisella tularensis*: Tularemia** 309
Anders Johansson, Herbert Tomaso, Plamen Padeshki, Anders Sjostedt, Nigel Silman, and Paola Pilo
Recommended Respiratory Protection 309
Recommended Personal Protective Equipment 309
Best Disinfection/Decontamination 309
Prevention 310
Case Reports, Ongoing Clinical Trials 310
Post Exposure Prophylaxis 310
Known Laboratory Accidents 310
Procedure Recommended in Case of Laboratory Spill or Other Type of Accident 310
Treatment of Disease 311
Clinical Guidelines 311
References 311
- 7** ***Yersinia pestis*: Plague** 312
Anne Laudisoit, Werner Ruppitsch, Anna Stoeger, and Ariane Pietzka
Recommended Respiratory Protection 312
Recommended Personal Protective Equipment 312
Best Disinfection 312
Surface and Equipment 312
Best Decontamination 313
Skin/Wound Disinfection 313
Prevention 313
Case Reports, Ongoing Clinical Trials 313
Post Exposure Prophylaxis 314

Known Laboratory Accidents 314
Procedure Recommended in Case of Laboratory Spill or Other Type of
Accident 314
Treatment of Disease 314
Prophylactic Therapy 315
Clinical Guidelines 315
References 316

- 8** ***Rickettsia* Species: Rickettsioses** 318
*Alice N. Maina, Stephanie Speck, Eva Spitalska, Rudolf Toman, Gerhard
Dobler, and Sally J. Cutler*
Recommended Respiratory Protection 318
Recommend Personal Protective Equipment 318
Best Disinfection 319
Best Decontamination 319
Prevention 319
Post Exposure Prophylaxis 319
Known Laboratory Accidents 319
Procedure Recommended in Case of Laboratory Spill or Other Type of
Accident 320
Treatment of Disease 320
Clinical Guidelines 320
References 320

- 9** ***Mycobacterium tuberculosis*: Tuberculosis** 322
*Stefan Panaiotov, Massimo Amicosante, Marc Govaerts,
Patrick Butaye, Elizabeta Bachiyiska, Nadia Brankova, and
Victoria Levterova*
Recommended Respiratory Protection 322
Recommended Personal Protective Equipment 322
Best Disinfection 323
Surface and Equipment 323
Best Decontamination 323
Prevention 323
Ongoing Clinical Trials 323
Post Exposure Prophylaxis 324
Known Laboratory Accidents 324
Procedure Recommended in Case of Laboratory Spill or Other Type of
Accident 324
Treatment of Disease 324
Clinical Guidelines 324
References 325

Part II Viruses 326

- 10 Influenza Virus: Highly Pathogenic Avian Influenza 328**
Chantal J. Snoeck and Claude P. Muller
 Recommended Respiratory Protection 328
 Recommended Personal Protective Equipment 328
 Best Disinfection 329
 Best Decontamination 329
 Prevention 329
 Vaccines with Marketing Authorization from the European Medicines Agency 330
 Post Exposure Prophylaxis 330
 Procedure Recommended in Case of Laboratory Spill or Other Type of Accident 331
 Treatment of Disease 331
 References 331
- 11 Variola: Smallpox 334**
Andreas Nitsche and Hermann Meyer
 Recommended Respiratory Protection 334
 Recommended Personal Protective Equipment 334
 Best Disinfection 334
 Best Decontamination 335
 Prevention 335
 Case Reports, Ongoing Clinical Trials 335
 Post Exposure 335
 Laboratory Accidents 336
 Procedure Recommended in Case of Laboratory Spill or Other Type of Accident 336
 Treatment of Disease 336
 References 337
- 12 Arenaviruses: Hemorrhagic Fevers 338**
Amy C. Shurtleff, Steven B. Bradfute, Sheli R. Radoshitzky, Peter B. Jahrling, Jens H. Kuhn, and Sina Bavari
 Category 338
 Recommended Respiratory Protection and Personal Protective Equipment 338
 Best Disinfection 339
 Best Decontamination 340
 Prevention 340
 Laboratory Accidents 341
 Procedure Recommended in the Case of Laboratory Spill or Other Accident 341
 Treatment of Disease 342
 References 342

- 13 Filoviruses: Hemorrhagic Fevers 344**
Victoria Wahl-Jensen, Sheli R. Radoshitzky, Sina Bavari, Peter B. Jahrling, and Jens H. Kuhn
Recommended Respiratory Protection and Particular Personal Protective Equipment 344
Disinfection/Decontamination 344
Prevention 345
Post Exposure Prophylaxis 345
Laboratory Accidents 346
Procedure Recommended in the Case of Laboratory Spill or Other Type of Accident 346
Accident with Personnel Involvement 346
Treatment of Disease 346
References 347
- 14 Bunyavirus 350**
- 14.1 Crimean Congo Hemorrhagic Fever Virus 351**
Ali Mirazimi
Recommended Respiratory Protection 351
Recommended Personal Protective Equipment 351
Best Disinfection 351
Best Decontamination 351
Prevention 352
Case Reports 352
Laboratory Accidents 352
Procedure Recommended in the Case of Laboratory Spill or Other Type of Accident 352
Treatment of Disease 352
Clinical Guidelines 353
- 14.2 Rift Valley Fever Virus: a Promiscuous Vector Borne Virus 354**
Manfred Weidmann, F. Xavier Abad, and Janusz T. Paweska
Recommended Respiratory Protection 354
Recommended Personal Protective Equipment 354
Best Disinfection 354
Best Decontamination 355
Prevention 355
Known Laboratory Accidents 356
Procedure Recommended in the Case of Laboratory Spill or Other Type of Accident 356
Treatment of Disease 356
References 356

14.3	Hantaviruses: the Most Widely Distributed Zoonotic Viruses on Earth	358
	<i>Jonas Klingström</i>	
	Recommended Respiratory Protection	358
	Recommended Personal Protective Equipment	358
	Best Disinfection	358
	Best Decontamination	358
	Prevention	359
	Post Exposure Prophylaxis Available?	359
	Laboratory Accidents	359
	Procedure Recommended in the Case of Laboratory Spill or Other Type of Accident	359
	Treatment of Disease	359
	Clinical Guidelines	359
	References	360
	Index	361